Osteoporosis
Osteoporosis (porous bones) is a progressive bone disease that is characterized by a decrease in bone density with an increased risk of fractures. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density of 2.5 standard deviations or more below the mean peak bone mass (average of young, healthy adults) as measured by dual-energy X-ray absorptiometry. The most common form of osteoporosis occurs in women after menopause. Senile osteoporosis occurs after age 75 and is seen in both females and males at a ratio of 2:1. Secondary osteoporosis occurs at any age and affects men and women equally. Chronic predisposing medical problems or prolonged use of medications such as glucocorticoids cause secondary osteoporosis. A number of medications can increase the risk of osteoporosis.
Clinical consequences of osteoporosis
The main problem associated with osteoporosis is the risk for bone fractures. In the elderly osteoporosis can be associated with chronic pain due to fractures and can lead to further disability and early mortality. Fractures are of the wrist, spine, shoulder and hip are the most common. Vertebral compression fractures are associated with back pain and shooting pain due to nerve root compression. Rarely spinal cord compression can occur and be life-threatening. Multiple vertebral fractures can lead to a stooped posture, loss of height, and chronic pain with resultant reduction in mobility. Fractures of the long bones, such as hip fracture, require prompt surgery.
Diagnosis
The diagnosis of osteoporosis can be made using conventional radiography and by measuring the bone mineral density (BMD) by using a method such as dual-energy x-ray absorptiometry. Since many medical conditions can cause osteoporosis it is important to perform appropriate blood tests to rule out an underlying problem, such as metastatic cancer, multiple myeloma, Cushing's disease.
Prevention
Lifestyle changes such as diet, reduced alcohol, exercise and avoiding falls are all important to reduce the risk associated with osteoporosis.
Recommended Reading
http://consensus.nih.gov/2000/2000osteoporosis111html.htm
http://nof.org/files/nof/public/content/file/344/upload/159.pdf
-
MicroVue BAP provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.
-
The MicroVue CICP assay measures type I C-terminal collagen propeptide (CICP) in serum. CICP may be useful as a biochemical indicator of collagen production...
-
The MicroVue Creatinine assay is offered as a convenience for researchers with no other means to perform the test.
-
MicroVue DPD is laboratory test that measures deoxypyridinoline cross-links (Dpd), a specific marker of bone resorption which is excreted in the urine.
-
The MicroVue Osteocalcin immunoassay measures intact (de novo) osteocalcin in serum.
-
MicroVue PYD provides a quantitative measure of pyridinium cross-links (Pyd and Dpd) as an indicator of type I collagen resorption, especially bone collagen...
-
MicroVue Serum PYD provides a quantitative measure of the excretion of pyridinoline cross-link (Pyd) in serum.
-
The MicroVue TRAP5b EIA is an immunocapture enzyme assay for the determination of tartrate-resistant acid phosphatase isoform 5b (TRAcP 5b) in human...
-
This kit is intended for research use only in the determination of mouse osteocalcin levels in serum, plasma or cell culture media.
-
This kit is intended for research use only in the determination of rat intact osteocalcin levels in serum, plasma or cell culture media.